Designations: | MDA-MB-231 | Depositors: | R Cailleau | Biosafety Level: | 1 | Shipped: | frozen | Medium & Serum: | See Propagation | Growth Properties: | adherent | Organism: | Homo sapiens (human) | Morphology: | epithelial | | Source: | Organ: mammary gland; breast Cell type: epithelial Disease: adenocarcinoma Derived from metastatic site: pleural effusion | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | Related Cell Culture Products | Applications: | transfection host (technology from amaxa Roche FuGENE® Transfection Reagents) | Receptors: | epidermal growth factor (EGF), expressed transforming growth factor alpha (TGF alpha), expressed | Tumorigenic: | Yes, in ALS treated BALB/c mice, forms poorly differentiated adenocarcinoma (grade III) Yes, in nude mice, forms poorly differentiated adenocarcinoma (grade III) | DNA Profile (STR): | Amelogenin: X CSF1PO: 12,13 D13S317: 13 D16S539: 12 D5S818: 12 D7S820: 8,9 THO1: 7,9.3 TPOX: 8,9 vWA: 15,18 | Cytogenetic Analysis: | The cell line is aneuploid female (modal number = 64, range = 52 to 68), with chromosome counts in the near-triploid range. Normal chromosomes N8 and N15 were absent. Eleven stable rearranged marker chromosomes are noted as well as unassignable chromosomes in addition to the majority of autosomes that are trisomic. Many of the marker chromosomes are identical to those shown in the karyotype reported by K.L. Satya-Prakash, et al. | Isoenzymes: | AK-1, 1; ES-D, 1; G6PD, B; GLO-I, 2; Me-2, 1-2; PGM1, 1-2; PGM3, 1 | Age: | 51 years adult | Gender: | female | Ethnicity: | Caucasian | Comments: | The cells express the WNT7B oncogene [PubMed: ]. | Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitzs L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0C Atmosphere: air, 100% | Subculturing: | Protocol: - Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C without CO2.
Subcultivation ratio: A subcultivation ratio of 1:2 to 1:4 is recommended Medium renewal: 2 to 3 times per week | Preservation: | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase | Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium): ATCC 30-2008 recommended serum: ATCC 30-2020 purified DNA: ATCC HTB-26D | References: | 1206: Brinkley BR , et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 22182: Cruciger Q , et al. Morphological, biochemical and chromosomal characterization of breast tumor lines from pleural effusions. In Vitro 12: 331, 1976. 22429: Siciliano MJ , et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779 22532: Cailleau R , et al. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53: 661-674, 1974. PubMed: 22656: Cailleau R , et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202 22977: Bates SE , et al. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 126: 596-607, 1990. PubMed: 23010: Dickstein B , et al. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J. Cell. Physiol. 157: 110-118, 1993. PubMed: 23113: Huguet EL , et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 54: 2615-2621, 1994. PubMed: 26321: Satya-Prakash KL , et al. Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes. Cancer Genet. Cytogenet. 3: 61-73, 1981. PubMed: 32272: Katayose Y , et al. Promoting apoptosis: a novel activity associated with the Cyclin-dependent kinase inhibitor p27. Cancer Res. 57: 5441-5445, 1997. PubMed: 32275: Littlewood-Evans AJ , et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 32341: Sheng S , et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA 93: 11669-11674, 1996. PubMed: 32489: De Vincenzo R , et al. Antiproliferative activity of colchicine analogues on MDR-positive and MDR-negative human cancer cell lines. Anticancer Drug Des. 13: 19-33, 1998. PubMed: 33021: Soker S , et al. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-endoded domain. J. Biol. Chem. 271: 5761-5767, 1996. PubMed: | |